Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

788
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
788
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same author

The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.

Cancer·2026
Same author

Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program.

The oncologist·2026
Same author

A time-varying geospatial model of habitat suitability for Japanese encephalitis virus vectors and vertebrate hosts in Australia.

PLoS neglected tropical diseases·2026
Same author

Health Inequity of Stage and Survival of Gastric Cancer in California.

Cancers·2025
Same author

Decoding Destiny: Can We Deliver Artificial Intelligence-Powered Patient-centered Care?

Cancer journal (Sudbury, Mass.)·2025

Related Experiment Video

Updated: Feb 20, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Prognostic and predictive biomarkers post curative intent therapy.

Rebecca Feldman1, Edward S Kim2

  • 1Department of Solid Tumor Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.

Annals of Translational Medicine
|October 24, 2017
PubMed
Summary

Early lung cancer diagnosis reduces mortality, but survival remains low due to recurrence. New predictive markers are needed for personalized adjuvant therapy in early-stage lung cancer patients.

Keywords:
Adjuvantbiomarkerslung cancer

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.9K

Related Experiment Videos

Last Updated: Feb 20, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.9K

Area of Science:

  • Oncology
  • Translational Medicine

Background:

  • Large-scale screening trials show early lung cancer diagnosis significantly reduces mortality.
  • Despite improved early detection, 5-year survival for early-stage lung cancer remains suboptimal (30-50%).
  • High recurrence rates necessitate improved adjuvant treatment strategies and predictive markers for therapy selection.

Purpose of the Study:

  • To review advancements in clinical management of early-stage lung cancer.
  • To discuss the development of patient selection tools for personalized treatment.
  • To explore the role of predictive markers in refining adjuvant therapy.

Main Methods:

  • Review of large-scale screening trials.
  • Analysis of molecular alterations and signatures for prognostic and predictive utility.
  • Evaluation of current patient selection tools in clinical practice.

Main Results:

  • Early diagnosis improves lung cancer survival rates.
  • Significant challenges persist in improving 5-year survival due to recurrence.
  • Many molecular markers have shown promise but have not translated into clinical tools.

Conclusions:

  • Improved treatment strategies are crucial for early-stage lung cancer patients with high recurrence risk.
  • Development of reliable predictive markers is essential for personalized adjuvant therapy.
  • Further research into patient selection tools is needed to refine early-stage lung cancer management.